Tiziana was previously notified by Nasdaq on January 29, 2025 that it was not in compliance with the minimum bid-price listing rule (under Rule 5550 (a) (2)) because its common stock failed to meet ...

These include super-trillion fully human antibody discovery platform, super-trillion common light chain antibody discovery platform, super-trillion 2C type single-domain antibody discovery ...

Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.

Tremfya is a fully human antibody created to neutralise inflammation by blocking IL-23, a cytokine that plays a part in autoimmune and inflammatory diseases. It is currently approved in the US for ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

Announced positive data from Phase 1 clinical trial evaluating VG-3927 for potential treatment of Alzheimer’s Disease (AD); plans to initiate ...

is used to identify fully-human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable ...

These include super-trillion fully human antibody discovery platform, super-trillion common light chain antibody discovery platform, super-trillion 2C type single-domain antibody discovery platform, ...